|
US4626549A
(en)
*
|
1974-01-10 |
1986-12-02 |
Eli Lilly And Company |
Treatment of obesity with aryloxyphenylpropylamines
|
|
US4584404A
(en)
*
|
1974-01-10 |
1986-04-22 |
Eli Lilly And Company |
Substituted phenoxyphenylproply dimethylamines
|
|
JPS5283811A
(en)
*
|
1976-01-01 |
1977-07-13 |
Lilly Co Eli |
Aryloxy phenyl propylamines and their salts
|
|
GB1570613A
(en)
*
|
1976-10-27 |
1980-07-02 |
Akzo Nv |
Biologically active tricyclic compounds and pharmaceutical compositions containing same
|
|
IL56369A
(en)
*
|
1978-01-20 |
1984-05-31 |
Erba Farmitalia |
Alpha-phenoxybenzyl propanolamine derivatives,their preparation and pharmaceutical compositions comprising them
|
|
FR2432500A1
(fr)
*
|
1978-02-24 |
1980-02-29 |
Roussel Uclaf |
Nouveaux derives de la benzene propanamine et leurs sels, procede de preparation et application a titre de medicaments
|
|
FR2455571A2
(fr)
*
|
1979-02-15 |
1980-11-28 |
Roussel Uclaf |
Nouveaux derives de la benzene propanamine et leurs sels, procede de preparation et application a titre medicaments
|
|
DE3017812A1
(de)
*
|
1980-05-09 |
1981-11-12 |
Merck Patent Gmbh, 6100 Darmstadt |
Cyclopropanderivate, diese enthaltende pharmazeutische zubereitungen und verfahren zu ihrer herstellung
|
|
US4430319A
(en)
|
1982-05-21 |
1984-02-07 |
State University Of New York |
Radioactive iodine labeled phenolic amines
|
|
US4824868A
(en)
*
|
1982-09-07 |
1989-04-25 |
Ciba-Geigy Corporation |
Propylamine derivatives useful for the treatment of dementia
|
|
US4692469A
(en)
*
|
1982-09-07 |
1987-09-08 |
Ciba-Geigy Corporation |
Propylamine derivatives
|
|
US4590213A
(en)
*
|
1983-04-08 |
1986-05-20 |
Eli Lilly And Company |
Anti-anxiety method
|
|
HU207282B
(en)
*
|
1984-05-31 |
1993-03-29 |
Chinoin Gyogyszer Es Vegyeszet |
Process for producing phenyl-alkyl-amine derivatives and pharmaceutical compositions containing them
|
|
US4683235A
(en)
*
|
1985-02-25 |
1987-07-28 |
Eli Lilly And Company |
Analgesic method
|
|
US4594358A
(en)
*
|
1985-02-25 |
1986-06-10 |
Eli Lilly And Company |
Analgesic method
|
|
US4777291A
(en)
*
|
1985-02-27 |
1988-10-11 |
Eli Lilly And Company |
Racemization process
|
|
US4956388A
(en)
*
|
1986-12-22 |
1990-09-11 |
Eli Lilly And Company |
3-aryloxy-3-substituted propanamines
|
|
US5135947A
(en)
*
|
1987-04-09 |
1992-08-04 |
Eli Lilly And Company |
1-phenyl-3-naphthalenyloxypropanamines and their use as selective serotonin reuptake inhibitors
|
|
ZA885824B
(en)
*
|
1987-08-14 |
1989-04-26 |
Merrell Dow Pharma |
Novel antidepressants
|
|
US5149714A
(en)
*
|
1987-08-14 |
1992-09-22 |
Merrell Dow Pharmaceuticals Inc. |
Antidepressants
|
|
US5223540A
(en)
*
|
1987-10-22 |
1993-06-29 |
Massachusetts Institute Of Technology |
Method for treating the premenstrual or late luteal phase syndrome
|
|
US4971998A
(en)
*
|
1987-10-22 |
1990-11-20 |
Massachusetts Institute Of Technology |
Methods for treating the premenstrual or late luteal phase syndrome
|
|
US4876282A
(en)
*
|
1987-11-25 |
1989-10-24 |
Eli Lilly And Company |
1-Phenylalkylamines as selective serotonin uptake inhibitors
|
|
US4996235A
(en)
*
|
1987-11-25 |
1991-02-26 |
Eli Lilly And Company |
3,4-diphenylbutanamines
|
|
US5238959A
(en)
*
|
1988-04-08 |
1993-08-24 |
Eli Lilly And Company |
3-phenyloxy-3-phenyl propanamines
|
|
CA1337128C
(en)
*
|
1988-04-08 |
1995-09-26 |
David Wayne Robertson |
Propanamine derivatives
|
|
US5250571A
(en)
*
|
1988-11-14 |
1993-10-05 |
Eli Lilly And Company |
(S)-norfluoxetine in method of inhibiting serotonin uptake
|
|
US4902710A
(en)
*
|
1988-12-14 |
1990-02-20 |
Eli Lilly And Company |
Serotonin and norepinephrine uptake inhibitors
|
|
US5114976A
(en)
*
|
1989-01-06 |
1992-05-19 |
Norden Michael J |
Method for treating certain psychiatric disorders and certain psychiatric symptoms
|
|
IT1228209B
(it)
*
|
1989-01-10 |
1991-06-05 |
Grato Magnone |
Procedimento per la preparazione di fluoxetina cloridrato.
|
|
FI81083C
(fi)
*
|
1989-03-03 |
1990-09-10 |
Orion Yhtymae Oy |
Ett foerbaettrat foerfarande foer framstaellning av n-metyl-3-(p-trifluormetylfenoxi)-3-fenylpropylamin hydroklorid.
|
|
US5166437A
(en)
*
|
1989-03-03 |
1992-11-24 |
Orion-Yhtyma Oy |
Process for the preparation of fluoxetine
|
|
DK258389D0
(da)
*
|
1989-05-26 |
1989-05-26 |
Ferrosan As |
Aryloxyphenylpropylaminer, deres fremstilling og anvendelse
|
|
JPH0375680U
(US08124317-20120228-C00018.png)
*
|
1989-11-21 |
1991-07-30 |
|
|
|
US5021426A
(en)
*
|
1990-02-26 |
1991-06-04 |
Merck & Co., Inc. |
Method of traeting malaria with cyproheptadine derivatives
|
|
US5250572A
(en)
*
|
1990-03-29 |
1993-10-05 |
Eli Lilly And Company |
(R)-norfluoxetine in method for occupying serotonin IC receptors
|
|
US5356934A
(en)
*
|
1990-03-29 |
1994-10-18 |
Eli Lilly And Company |
Selected serotonin subtype receptor agonist to treat sleep apnea
|
|
US5589511A
(en)
*
|
1990-08-13 |
1996-12-31 |
Sepracor Inc. |
Method for treating migraine headaches using optically pure S(+) fluoxetine
|
|
US5708035A
(en)
*
|
1991-02-04 |
1998-01-13 |
Sepracor Inc. |
Methods of use and compositions of R(-) fluoxetine
|
|
AU642582B2
(en)
*
|
1991-02-25 |
1993-10-21 |
Eli Lilly And Company |
Treatment of lower urinary tract disorders
|
|
US5136079A
(en)
*
|
1991-02-26 |
1992-08-04 |
Eli Lilly And Company |
Regioselective synthesis
|
|
US5136078A
(en)
*
|
1991-02-26 |
1992-08-04 |
Eli Lilly And Company |
Synthesis of b-cyanohydrins
|
|
US5320825A
(en)
*
|
1991-05-01 |
1994-06-14 |
Trustees Of The University Of Pennsylvania |
Serotonin reuptake inhibitors for S.P.E.C.T. imaging
|
|
WO1993000811A1
(en)
*
|
1991-07-01 |
1993-01-21 |
The General Hospital Corporation |
Invertebrate phenylethanolamine transporter and the use thereof
|
|
IL99316A
(en)
|
1991-08-27 |
1995-03-15 |
Teva Pharma |
Production of fluoxetine and new intermediates
|
|
US5202319A
(en)
*
|
1991-09-23 |
1993-04-13 |
Hoechst-Roussel Pharmaceuticals Inc. |
Substituted 3-amino-2,3,4,5-tetrahydro-1-aryloxy-3-benzazepines
|
|
EP0537915B1
(en)
*
|
1991-09-27 |
1995-07-12 |
Eli Lilly And Company |
N-alkyl-3-phenyl-3-(2-alkylthiophenoxy)propylamines as norepinephrine inhibitors
|
|
US5281624A
(en)
*
|
1991-09-27 |
1994-01-25 |
Eli Lilly And Company |
N-alkyl-3-phenyl-3-(2-substituted phenoxy) propylamines and pharmaceutical use thereof
|
|
HU9202128D0
(en)
*
|
1992-06-26 |
1992-10-28 |
Richter Gedeon Vegyeszet |
Method for producing n-methyl-(3-phenyl-3-(4-[trifluoro-methyl])-phenooxi-)-amine
|
|
EP0576766A1
(en)
*
|
1992-06-29 |
1994-01-05 |
Novo Nordisk A/S |
Propanolamine derivatives, their preparation and use
|
|
US7087765B2
(en)
*
|
1995-06-07 |
2006-08-08 |
Nps Pharmaceuticals, Inc. |
Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
|
|
US6017965A
(en)
*
|
1993-02-08 |
2000-01-25 |
Nps Pharmaceuticals, Inc. |
Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
|
|
TW344661B
(en)
*
|
1993-11-24 |
1998-11-11 |
Lilly Co Eli |
Pharmaceutical composition for treatment of incontinence
|
|
CA2134038C
(en)
*
|
1994-06-16 |
1997-06-03 |
David Taiwai Wong |
Potentiation of drug response
|
|
ES2082723B1
(es)
|
1994-07-20 |
1996-10-01 |
Lilly Sa |
Formulacion farmaceutica de fluoxetina en forma dispersable.
|
|
EP0714663A3
(en)
|
1994-11-28 |
1997-01-15 |
Lilly Co Eli |
Potentiation of drug responses by serotonin 1A receptor antagonists
|
|
US5576321A
(en)
*
|
1995-01-17 |
1996-11-19 |
Eli Lilly And Company |
Compounds having effects on serotonin-related systems
|
|
US5741789A
(en)
|
1995-01-17 |
1998-04-21 |
Eli Lilly And Company |
Compounds having effects on serotonin-related systems
|
|
ES2101650B1
(es)
*
|
1995-06-29 |
1998-01-16 |
Lilly Sa |
Procedimiento de preparacion de n-metil-3-fenil-3-(p-trifluorometilfenoxi) propilamina.
|
|
US6548084B2
(en)
*
|
1995-07-20 |
2003-04-15 |
Smithkline Beecham Plc |
Controlled release compositions
|
|
ES2101654B1
(es)
*
|
1995-07-24 |
1998-01-16 |
Lilly Sa |
Procedimiento de preparacion de n-metil-3-fenil-3-(p-trifluorometilfe noxi) propilamina.
|
|
ES2101655B1
(es)
*
|
1995-07-28 |
1998-01-16 |
Lilly Sa |
Procedimiento de preparacion de n-metil-3-fenil-3-(p-trifluorometilfe noxi) propilamina.
|
|
ES2103680B1
(es)
*
|
1995-08-03 |
1998-04-01 |
Lilly Sa |
Procedimiento de preparacion de n-metil-3-fenil-3- (p-trifluorometilfenoxi)propilamina.
|
|
EP0759299B1
(en)
*
|
1995-08-16 |
2000-04-26 |
Eli Lilly And Company |
Potentiation of serotonin response
|
|
ES2103681B1
(es)
*
|
1995-09-19 |
1998-04-01 |
Lilly Sa |
Procedimiento de preparacion de n-metil-3-fenil - (p-trifluorometilfenoxi) propilamina.
|
|
IT1283141B1
(it)
*
|
1996-07-11 |
1998-04-07 |
Laporte Organics Francis S P A |
Procedimento per la preparazione di n-metil-3-(p-trifluorometilfenossi)-3-fenilpropilamina e dei suoi
|
|
US6512010B1
(en)
*
|
1996-07-15 |
2003-01-28 |
Alza Corporation |
Formulations for the administration of fluoxetine
|
|
US5830500A
(en)
*
|
1996-07-22 |
1998-11-03 |
Pentech Pharmaceuticals, Inc. |
Low dose fluoxetine tablet
|
|
ZA977967B
(en)
*
|
1996-09-23 |
1999-03-04 |
Lilly Co Eli |
Combination therapy for treatment of psychoses
|
|
US6203817B1
(en)
|
1997-02-19 |
2001-03-20 |
Alza Corporation |
Reduction of skin reactions caused by transdermal drug delivery
|
|
US5910319A
(en)
*
|
1997-05-29 |
1999-06-08 |
Eli Lilly And Company |
Fluoxetine enteric pellets and methods for their preparation and use
|
|
PT1030667E
(pt)
*
|
1997-11-14 |
2005-06-30 |
Akzo Nobel Nv |
Utilizacao de mirtazapina para o fabrico de um medicamento para o tratamento de apenas do sono
|
|
US5936124A
(en)
*
|
1998-06-22 |
1999-08-10 |
Sepacor Inc. |
Fluoxetine process from benzoylpropionic acid
|
|
US6025517A
(en)
*
|
1998-08-03 |
2000-02-15 |
Sepracor Inc. |
Fluoxetine process from benzoylacetonitrile
|
|
AU2180400A
(en)
*
|
1999-01-13 |
2000-08-01 |
Eli Lilly And Company |
A pharmaceutical combination for the treatment of depression
|
|
FR2791345B1
(fr)
*
|
1999-03-26 |
2001-05-04 |
Adir |
Nouveaux derives du benzo[3,4]cyclobuta[1,2-c]pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
|
|
AU3219800A
(en)
*
|
1999-03-29 |
2000-10-16 |
Eli Lilly And Company |
Stereospecific method for preparing tomoxetine and intermediates thereof
|
|
UA75580C2
(uk)
*
|
1999-09-03 |
2006-05-15 |
Апбі Холдінгс, Ллк |
Застосування дапоксетину або його фармацевтично прийнятної солі в лікарському засобі для лікування розладу статевої функції та промисловий виріб для його застосування
|
|
US6677485B2
(en)
|
1999-12-17 |
2004-01-13 |
Ranbaxy Laboratories Limited |
Process for the preparation of fluoxetine hydrochloride
|
|
GB0004151D0
(en)
*
|
2000-02-23 |
2000-04-12 |
Astrazeneca Uk Ltd |
Novel use
|
|
GB0004152D0
(en)
*
|
2000-02-23 |
2000-04-12 |
Astrazeneca Uk Ltd |
Novel compounds
|
|
GB0004153D0
(en)
*
|
2000-02-23 |
2000-04-12 |
Astrazeneca Uk Ltd |
Novel use
|
|
GB0004149D0
(en)
*
|
2000-02-23 |
2000-04-12 |
Astrazeneca Uk Ltd |
Novel compounds
|
|
US6273260B1
(en)
|
2000-03-08 |
2001-08-14 |
Eli Lilly And Company |
Pharmaceutical packaging system
|
|
GB2357762B
(en)
*
|
2000-03-13 |
2002-01-30 |
Lundbeck & Co As H |
Crystalline base of citalopram
|
|
EP1284729A4
(en)
*
|
2000-04-13 |
2007-12-19 |
Mayo Foundation |
REDUCTION AGENTS OF A (BETA) 42
|
|
IL139975A0
(en)
*
|
2000-11-29 |
2002-02-10 |
Univ Ramot |
Anti proliferative drugs
|
|
US20050013853A1
(en)
*
|
2000-11-29 |
2005-01-20 |
Irit Gil-Ad |
Anti-proliferative drugs
|
|
US6310251B1
(en)
|
2001-01-31 |
2001-10-30 |
Grayson Walker Stowell |
Form a of fluoxetine hydrochloride
|
|
US6316672B1
(en)
|
2001-01-31 |
2001-11-13 |
Grayson Walker Stowell |
Form a of fluoxetine hydrochloride
|
|
US6258853B1
(en)
|
2001-01-31 |
2001-07-10 |
Grayson Walker Stowell |
Form a of fluoxetine hydrochloride
|
|
US6313350B1
(en)
|
2001-01-31 |
2001-11-06 |
Grayson Walker Stowell |
Form a of fluoxetine hydrochloride
|
|
US6310250B1
(en)
|
2001-01-31 |
2001-10-30 |
Grayson Walker Stowell |
Form A of fluoxetine hydrochloride
|
|
WO2002070457A1
(en)
*
|
2001-03-06 |
2002-09-12 |
Eli Lilly And Company |
Inhibitor of monoamine uptake
|
|
US6645946B1
(en)
|
2001-03-27 |
2003-11-11 |
Pro-Pharmaceuticals, Inc. |
Delivery of a therapeutic agent in a formulation for reduced toxicity
|
|
AR035700A1
(es)
*
|
2001-05-08 |
2004-06-23 |
Astrazeneca Ab |
Derivados de arilheteroalquilamina, composicion farmaceutica, usos de estos derivados para la fabricacion de medicamentos, metodos de tratamiento, y proceso para la preparacion de estos derivados
|
|
US7034059B2
(en)
*
|
2001-07-02 |
2006-04-25 |
Sepracor Inc. |
Methods of using norfluoxetine
|
|
EP2147679B1
(en)
|
2001-07-25 |
2014-06-25 |
Raptor Pharmaceutical, Inc. |
Compositions for blood-brain barrier transport
|
|
SE0102640D0
(sv)
*
|
2001-07-31 |
2001-07-31 |
Astrazeneca Ab |
Novel compounds
|
|
SE0102641D0
(sv)
*
|
2001-07-31 |
2001-07-31 |
Astrazeneca Ab |
Novel compounds
|
|
MXPA04000979A
(es)
*
|
2001-07-31 |
2005-02-17 |
Upjohn Co |
Tratamiento de dolor cronico con 3-ariloxi-3-fenilpropanaminas.
|
|
US20040170688A1
(en)
*
|
2001-08-06 |
2004-09-02 |
Deshmukh Abhijit Mukund |
Enteric formulation of fluoxetin
|
|
WO2003013480A1
(en)
|
2001-08-06 |
2003-02-20 |
Dr. Reddy's Laboratories Ltd. |
Improved enteric formulation of fluoxetin
|
|
US6630454B2
(en)
|
2001-09-10 |
2003-10-07 |
Ramot At Tel-Aviv University Ltd. |
Method and pharmaceutical composition for the treatment of cancer
|
|
EP1434763B1
(en)
*
|
2001-10-12 |
2018-01-17 |
Azevan Pharmaceuticals, Inc. |
Beta-lactamyl vasopressin v1a antagonists
|
|
US20040034106A1
(en)
*
|
2001-11-06 |
2004-02-19 |
Read Holly Ann |
Treatment of anxiety disorders
|
|
ES2287338T3
(es)
*
|
2001-11-30 |
2007-12-16 |
Eli Lilly And Company |
Uso de inhibidores de recaptacion de norepinefrina para el tratamiento de trastornos de tics.
|
|
DE60223718T2
(de)
*
|
2001-12-11 |
2008-10-30 |
Eli Lilly And Co., Indianapolis |
Verwendung von norepinephrin wiederaufnahmehemmern zur behandlung von kognitiven störungen
|
|
JP4625637B2
(ja)
|
2002-02-22 |
2011-02-02 |
シャイア エルエルシー |
活性物質送達系及び活性物質を保護し投与する方法
|
|
WO2003102158A2
(en)
*
|
2002-05-31 |
2003-12-11 |
The Forsyth Institute |
Methods for increasing bone density
|
|
JP2004077714A
(ja)
*
|
2002-08-15 |
2004-03-11 |
Fuji Xerox Co Ltd |
光走査装置
|
|
SE0203304D0
(sv)
*
|
2002-11-07 |
2002-11-07 |
Astrazeneca Ab |
Novel Coumpounds
|
|
US6846957B2
(en)
*
|
2002-11-22 |
2005-01-25 |
Board Of Regents, The University Of Texas System |
Synthesis of 3-aminomethyl-1-propanol, a fluoxetine precursor
|
|
US20040235925A1
(en)
*
|
2002-12-17 |
2004-11-25 |
Pharmacia Corporation |
Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of duloxetine, venlafaxine or atomoxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
|
|
EP1603548A4
(en)
*
|
2003-02-05 |
2007-10-10 |
Myriad Genetics Inc |
COMPOSITION AND METHOD FOR TREATING NEURODEGENERATIVE DISORDERS
|
|
EP1620083A2
(en)
*
|
2003-04-18 |
2006-02-01 |
Pharmacia & Upjohn Company LLC |
Combination therapies
|
|
JP4901474B2
(ja)
*
|
2003-05-30 |
2012-03-21 |
ランバクシー ラボラトリーズ リミテッド |
置換ピロール誘導体
|
|
AU2004311577A1
(en)
*
|
2003-07-11 |
2005-07-21 |
Myriad Genetics, Inc. |
Pharmaceutical methods, dosing regimes and dosage forms for the treatment of Alzheimer's disease
|
|
US20060100290A1
(en)
*
|
2003-07-28 |
2006-05-11 |
Dunaway Leslie J |
Treatment of allergic rhinitis and asthma
|
|
CA2537402C
(en)
|
2003-09-12 |
2009-05-05 |
Pfizer Inc. |
Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline re-uptake inhibitors
|
|
KR101151653B1
(ko)
*
|
2003-09-17 |
2012-06-28 |
얀센 파마슈티카 엔.브이. |
융합된 헤테로사이클릭 화합물
|
|
US7671072B2
(en)
*
|
2003-11-26 |
2010-03-02 |
Pfizer Inc. |
Aminopyrazole derivatives as GSK-3 inhibitors
|
|
EP2343073A3
(en)
|
2003-12-11 |
2011-10-12 |
Sepracor Inc. |
Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
|
|
WO2005065673A1
(en)
*
|
2003-12-31 |
2005-07-21 |
Actavis Group Hf |
Atomoxetine formulations
|
|
US7893261B2
(en)
*
|
2004-03-26 |
2011-02-22 |
Baylor University |
Serotonin reuptake inhibitors
|
|
WO2006001877A2
(en)
*
|
2004-04-13 |
2006-01-05 |
Myriad Genetics, Inc. |
Combination treatment for neurodegenerative disorders comprising r-flurbiprofen
|
|
US20050233010A1
(en)
*
|
2004-04-19 |
2005-10-20 |
Satow Philip M |
Lithium combinations, and uses related thereto
|
|
EP1745180A1
(en)
*
|
2004-04-29 |
2007-01-24 |
Keystone Retaining Wall Systems, Inc. |
Veneers for walls, retaining walls and the like
|
|
WO2006020852A2
(en)
*
|
2004-08-11 |
2006-02-23 |
Myriad Genetics, Inc. |
Pharmaceutical composition and method for treating neurodegenerative disorders
|
|
WO2006020850A2
(en)
*
|
2004-08-11 |
2006-02-23 |
Myriad Genetics, Inc. |
Pharmaceutical composition and method for treating neurodegenerative disorders
|
|
BRPI0514303A
(pt)
*
|
2004-08-11 |
2008-06-10 |
Myriad Genetics Inc |
composição farmacêutica e método para tratar distúrbios neurodegenerativos
|
|
US20080004470A1
(en)
*
|
2004-09-27 |
2008-01-03 |
Mathad Vijayavitthal T |
Synthesis of Atomoxetine Hydrochloride
|
|
JP2007523213A
(ja)
*
|
2004-12-23 |
2007-08-16 |
テバ ファーマシューティカル インダストリーズ リミティド |
医薬的に許容できるデュロキセチンの塩及びその中間体の調製方法
|
|
US7399871B2
(en)
*
|
2005-03-08 |
2008-07-15 |
Teva Pharmaceutical Industries Ltd. |
Crystal forms of (S)-(+)-N,N-dimethyl-3-(1-naphthalenyloxy)-3-(2-thienyl)propanamine oxalate and the preparation thereof
|
|
WO2006099459A1
(en)
*
|
2005-03-14 |
2006-09-21 |
Teva Pharmaceutical Industries Ltd. |
Process for the preparation of optically active (s)-(+)-n,n-dimethyl-3-(1-naphthalenyloxy)-3-(2-thienyl)propanamine
|
|
US9597314B2
(en)
|
2005-03-22 |
2017-03-21 |
Azevan Pharmaceuticals, Inc. |
Beta-lactamylalkanoic acids for treating premenstrual disorders
|
|
GT200600165A
(es)
*
|
2005-04-22 |
2007-03-14 |
|
Derivados dihidrobenzofuranos y usos de los mismos
|
|
US20060252825A1
(en)
*
|
2005-04-22 |
2006-11-09 |
Wyeth |
Crystal forms of {[(2r)-7-(2,6-dichlorophenyl)-5-fluoro-2,3-dihydro-1-benzofuran-2-yl]methyl}amine hydrochloride
|
|
GT200600164A
(es)
|
2005-04-22 |
2007-03-14 |
|
Derivados de dihidrobenzofuranos y usos de los mismos
|
|
EP1871358A1
(en)
|
2005-04-22 |
2008-01-02 |
Wyeth |
Benzofuranyl alkanamine derivatives and uses thereof as 5-ht2c agonists
|
|
WO2006116718A2
(en)
|
2005-04-28 |
2006-11-02 |
Proteus Biomedical, Inc. |
Pharma-informatics system
|
|
US7485754B2
(en)
*
|
2005-07-08 |
2009-02-03 |
Apotex Pharmachem Inc. |
Efficient method for preparing 3-aryloxy-3-arylpropylamines and their optical stereoisomers
|
|
WO2007008758A2
(en)
*
|
2005-07-08 |
2007-01-18 |
Braincells, Inc. |
Methods for identifying agents and conditions that modulate neurogenesis
|
|
US20070015832A1
(en)
*
|
2005-07-14 |
2007-01-18 |
Myriad Genetics, Incorporated |
Methods of treating overactive bladder and urinary incontinence
|
|
KR101523776B1
(ko)
|
2005-07-19 |
2015-05-28 |
아제반 파마슈티칼스, 인코퍼레이티드 |
베타-락타민 페닐알라닌, 시스테인 그리고 세린 바소프레신길항물질
|
|
JP2009502807A
(ja)
*
|
2005-07-22 |
2009-01-29 |
ミリアド ジェネティクス， インコーポレイテッド |
薬剤含有率の高い製剤および投与量形態
|
|
US7598255B2
(en)
*
|
2005-08-04 |
2009-10-06 |
Janssen Pharmaceutica Nv |
Pyrimidine compounds as serotonin receptor modulators
|
|
EP2258358A3
(en)
|
2005-08-26 |
2011-09-07 |
Braincells, Inc. |
Neurogenesis with acetylcholinesterase inhibitor
|
|
US7842717B2
(en)
*
|
2005-09-22 |
2010-11-30 |
Teva Pharmaceutical Industries Ltd. |
DNT-maleate and methods of preparation thereof
|
|
US20080207923A1
(en)
*
|
2005-09-22 |
2008-08-28 |
Santiago Ini |
Pure DNT-maleate and methods of preparation thereof
|
|
JP2009512711A
(ja)
|
2005-10-21 |
2009-03-26 |
ブレインセルス，インコーポレイティド |
Ｐｄｅ阻害による神経新生の調節
|
|
CA2625210A1
(en)
|
2005-10-31 |
2007-05-10 |
Braincells, Inc. |
Gaba receptor mediated modulation of neurogenesis
|
|
AU2006313430B2
(en)
*
|
2005-11-08 |
2012-09-06 |
Ranbaxy Laboratories Limited |
Process for (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
|
|
CN1304360C
(zh)
*
|
2005-12-12 |
2007-03-14 |
天津大学 |
N,n－二甲基－3－羟基－3－芳基丙胺的制备方法
|
|
US20070191471A1
(en)
*
|
2006-01-23 |
2007-08-16 |
Santiago Ini |
DNT-fumarate and methods of preparation thereof
|
|
FR2912057B1
(fr)
*
|
2007-02-07 |
2009-04-17 |
Sanofi Aventis Sa |
Composition pharmaceutique contenant en association le saredutant et un inhibiteur selectif de la recapture de la serotonine ou un inhibiteur de la recapture de la serotonine/norepinephrine
|
|
US20100216734A1
(en)
*
|
2006-03-08 |
2010-08-26 |
Braincells, Inc. |
Modulation of neurogenesis by nootropic agents
|
|
AU2007223036A1
(en)
*
|
2006-03-08 |
2007-09-13 |
Braincells, Inc. |
Modulation of neurogenesis by nootropic agents
|
|
WO2008020314A2
(en)
*
|
2006-03-14 |
2008-02-21 |
Ranbaxy Laboratories Limited |
Statin stabilizing dosage formulations
|
|
CA2644662A1
(en)
*
|
2006-03-24 |
2007-10-04 |
Wyeth |
New therapeutic combinations for the treatment of depression
|
|
WO2007134136A2
(en)
|
2006-05-09 |
2007-11-22 |
Braincells, Inc. |
Neurogenesis by modulating angiotensin
|
|
US7858611B2
(en)
*
|
2006-05-09 |
2010-12-28 |
Braincells Inc. |
Neurogenesis by modulating angiotensin
|
|
US20100009983A1
(en)
*
|
2006-05-09 |
2010-01-14 |
Braincells, Inc. |
5 ht receptor mediated neurogenesis
|
|
AU2007249435A1
(en)
|
2006-05-09 |
2007-11-22 |
Braincells, Inc. |
5 HT receptor mediated neurogenesis
|
|
MX2008001079A
(es)
*
|
2006-05-23 |
2008-03-19 |
Teva Pharma |
Polimorfos de hidrocloruro de duloxetina.
|
|
US20080033045A1
(en)
*
|
2006-07-07 |
2008-02-07 |
Myriad Genetics, Incorporated |
Treatment of psychiatric disorders
|
|
AR063469A1
(es)
*
|
2006-07-14 |
2009-01-28 |
Ranbaxy Lab Ltd |
Formas polimorficas de ácido (3r,5r)-7-[2-(4-fluorofenil)-5-isopropil-3-fenil-4-[(4-hidroximetilfenilamino)carbonil]-pirrol-1-il]-3, 5-dihidroxi-heptanoico, sal hemicalcio, metodos de preparacion de las mismas, una composicion farmaceutica que las comprende y su uso en el tratamiento de enfermedades
|
|
TW200817003A
(en)
*
|
2006-07-31 |
2008-04-16 |
Sanofi Aventis |
Pharmaceutical composition comprising, in combination, saredutant and a selective serotonin peuptake inhibitor or a serotonin/norepinephrine reuptake inhibitor
|
|
WO2008026227A2
(en)
*
|
2006-08-28 |
2008-03-06 |
Matrix Laboratories Ltd |
A process for the preparation of atomoxetine hydrochloride
|
|
KR20090064418A
(ko)
*
|
2006-09-08 |
2009-06-18 |
브레인셀즈 인코퍼레이션 |
4-아실아미노피리딘 유도체 포함 조합물
|
|
WO2008034032A2
(en)
*
|
2006-09-14 |
2008-03-20 |
Azevan Pharmaceuticals, Inc. |
Beta-lactam cannabinoid receptor modulators
|
|
WO2008036678A2
(en)
*
|
2006-09-19 |
2008-03-27 |
Braincells, Inc. |
Combination comprising a peroxisome proliferator activated receptor agent and a second neurogenic agent for treating a nervous system disorder, increasing neurodifferentiation and increasing neurogenesis
|
|
US20100184806A1
(en)
|
2006-09-19 |
2010-07-22 |
Braincells, Inc. |
Modulation of neurogenesis by ppar agents
|
|
ITMI20061987A1
(it)
*
|
2006-10-16 |
2008-04-17 |
Archimica Srl |
Processo per la sintesi di arilossipropilammine ed eteroarilossipropilammine.
|
|
WO2008062473A1
(en)
*
|
2006-10-31 |
2008-05-29 |
Cadila Healthcare Limited |
Process for preparing atomoxetine hydrochloride
|
|
FR2910319B1
(fr)
|
2006-12-20 |
2011-06-03 |
Substipharm Dev |
Formulations pharmaceutiques dispersibles contenant de la fluoxetine
|
|
WO2008083204A2
(en)
*
|
2006-12-28 |
2008-07-10 |
Braincells, Inc. |
Modulation of neurogenesis by melatoninergic ligands
|
|
EP2125017A2
(en)
*
|
2007-01-11 |
2009-12-02 |
Braincells, Inc. |
Modulation of neurogenesis with use of modafinil
|
|
US8795627B2
(en)
|
2007-03-21 |
2014-08-05 |
Raptor Pharmaceuticals Inc. |
Treatment of liver disorders by administration of RAP conjugates
|
|
WO2008122019A1
(en)
*
|
2007-04-02 |
2008-10-09 |
Cypress Biosciences, Inc. |
Improving the tolerability of both mirtazapine and reboxetine by using them in combination
|
|
EP3524248A1
(en)
|
2007-06-21 |
2019-08-14 |
VeroScience LLC |
Method of treating metabolic disorders and depression with dopamine receptor agonists
|
|
WO2009141833A2
(en)
*
|
2008-04-17 |
2009-11-26 |
Ind-Swift Laboratories Limited |
An improved process for synthesizing highly pure atomoxetine
|
|
EP2288345B1
(en)
|
2008-04-18 |
2015-06-10 |
University College Dublin National University Of Ireland, Dublin |
Psycho-pharmaceuticals
|
|
JP5564517B2
(ja)
|
2009-02-20 |
2014-07-30 |
ティーオー − ビービービー ホールディング ベスローテン フェンノートシャップ |
グルタチオンをベースとする薬物送達システム
|
|
WO2010099217A1
(en)
|
2009-02-25 |
2010-09-02 |
Braincells, Inc. |
Modulation of neurogenesis using d-cycloserine combinations
|
|
CN102458374A
(zh)
|
2009-05-06 |
2012-05-16 |
实验室护肤股份有限公司 |
包含活性剂-磷酸钙颗粒复合物的皮肤递送组合物及其使用方法
|
|
WO2011027359A2
(en)
|
2009-07-30 |
2011-03-10 |
Matrix Laboratories Ltd |
Novel process for the preparation of 4-hydroxy atomoxetine
|
|
EP2348120B1
(en)
|
2009-12-30 |
2014-06-11 |
Universität Wien |
Enzymatic reduction of 1-phenylpropanone and derivatives thereof
|
|
CA2804001C
(en)
|
2010-07-01 |
2021-02-09 |
Azevan Pharmaceuticals, Inc. |
Methods for treating post traumatic stress disorder
|
|
WO2012020418A1
(en)
|
2010-08-12 |
2012-02-16 |
Matrix Laboratories Ltd |
Novel polymorphs of 4-hydroxy atomoxetine hydrochloride
|
|
US20120077778A1
(en)
|
2010-09-29 |
2012-03-29 |
Andrea Bourdelais |
Ladder-Frame Polyether Conjugates
|
|
JP2014508187A
(ja)
|
2011-03-17 |
2014-04-03 |
ルピン・リミテッド |
選択的セロトニン再取り込み阻害薬の放出制御医薬組成物
|
|
US20150174083A1
(en)
|
2012-07-31 |
2015-06-25 |
Sanovel Hayvan Sagligi Urunleri Sanayi Ve Ticaret Anonim Sirketi |
Use of fluoxetine for increasing meat and milk production
|
|
US20150190352A1
(en)
|
2012-07-31 |
2015-07-09 |
Sanovel Hayvan Sagligi Ürünleri Sanayi Ve Ticaret Anonim Sirketi |
Use of fluoxetine in animals
|
|
WO2014046544A1
(en)
|
2012-09-21 |
2014-03-27 |
Aapa B.V. |
Substituted 3-heteroaryloxy-3-(hetero)aryl-propylamines as serotonin transporter and serotonin ht2c receptor modulators
|
|
BR112016022575A2
(pt)
|
2014-03-28 |
2017-08-15 |
Azevan Pharmaceuticals Inc |
Composições e métodos para o tratamento de doenças neurodegenerativas
|
|
CN105777706B
(zh)
*
|
2014-12-25 |
2019-08-23 |
江苏恩华药业股份有限公司 |
一种3-[(苯并[d][1, 3]二氧戊环-4-基)-氧基]-3-芳基丙胺类化合物及其应用
|
|
CN111295373A
(zh)
|
2017-09-15 |
2020-06-16 |
阿泽凡药物公司 |
用于治疗脑损伤的组合物和方法
|
|
JP2022540706A
(ja)
|
2019-07-19 |
2022-09-16 |
バイオエクセル セラピューティクス，インコーポレイテッド |
鎮静作用のないデクスメデトミジン治療レジメン
|
|
US11806334B1
(en)
|
2023-01-12 |
2023-11-07 |
Bioxcel Therapeutics, Inc. |
Non-sedating dexmedetomidine treatment regimens
|
